Evelien Smits

Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women.

The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.

Immunotherapy of acute myeloid leukemia: current approaches.

The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells.

Dendritic cell-based cancer gene therapy.

Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties.

The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT.

Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination.

Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers.

Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents.

Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.

Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC.

Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?

Dendritic cell vaccination in acute myeloid leukemia.

Sampling site matters when counting lymphocyte subpopulations.

NK cells: key to success of DC-based cancer vaccines?

Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.

CD56 marks human dendritic cell subsets with cytotoxic potential.

Interferon α may be back on track to treat acute myeloid leukemia.

Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy.

Tumoricidal activity of human dendritic cells.

Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Loading of acute myeloid leukemia cells with poly(I:C) by electroporation.

Clinical use of dendritic cells for cancer therapy.

HPV vaccine stimulates cytotoxic activity of killer dendritic cells and natural killer cells against HPV-positive tumour cells.

Induction of cytomegalovirus-specific T cell responses in healthy volunteers and allogeneic stem cell recipients using vaccination with messenger RNA-transfected dendritic cells.

Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs.

Interleukin-15: new kid on the block for antitumor combination therapy.

Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functions.

Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner.

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.

Targeting immune checkpoints: New opportunity for mesothelioma treatment?

Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.

Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis.

Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.

Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials.

Transpresentation of interleukin-15 by IL-15/IL-15Rα mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity.

Generation and Cryopreservation of Clinical Grade Wilms' Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

Dendritic Cells as Vaccines: Key Regulators of Tolerance and Immunity.

The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.

Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells.

IL-15 receptor alpha as the magic wand to boost the success of IL-15 antitumor therapies: The upswing of IL-15 transpresentation.

Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity.

Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells.

Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

CD70 and PD-L1 in anaplastic thyroid cancer - promising targets for immunotherapy.

Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox.

Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion.

Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections.

CD56 in the Immune System: More Than a Marker for Cytotoxicity?

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia.

Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells.

Preclinical data on the combination of cisplatin and anti-CD70 therapy in non-small cell lung cancer as an excellent match in the era of combination therapy.

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients.

Anti-cancer capacity of plasma-treated PBS: effect of chemical composition on cancer cell cytotoxicity.

Increased herpes zoster risk associated with poor HLA-A immediate early 62 protein (IE62) affinity.

Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade.

Identification of survivin as a promising target for the immunotherapy of adult B-cell acute lymphoblastic leukemia.

Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer.

Combining top-ranked immunotherapeutics in lung cancer.

Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review.

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress.

Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.

The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy.

Unveiling a CD70-positive subset of cancer-associated fibroblasts marked by pro-migratory activity and thriving regulatory T cell accumulation.

Memory CD4 T cell receptor repertoire data mining as a tool for identifying cytomegalovirus serostatus.

Vaccine and immune cell therapy in non-small cell lung cancer.

Author Correction: Multidisciplinary study of the secondary immune response in grandparents re-exposed to chickenpox.

Transcriptome profiling in blood before and after hepatitis B vaccination shows significant differences in gene expression between responders and non-responders.

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

Reduction of Human Glioblastoma Spheroids Using Cold Atmospheric Plasma: The Combined Effect of Short- and Long-Lived Reactive Species.

Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing.

RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.

Non-Thermal Plasma as a Unique Delivery System of Short-Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells.

RANK-RANKL Signaling in Cancer of the Uterine Cervix: A Review.

CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15.

Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression.

Influence of Cell Type and Culture Medium on Determining Cancer Selectivity of Cold Atmospheric Plasma Treatment.

Desmoid tumors display a strong immune infiltration at the tumor margins and no PD-L1-driven immune suppression.

Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer.

The potential and controversy of targeting STAT family members in cancer.

Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells.

Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method.

Modifying the Tumour Microenvironment: Challenges and Future Perspectives for Anticancer Plasma Treatments.

New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.

Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?

Mass Spectrometry Imaging Reveals Neutrophil Defensins as Additional Biomarkers for Anti-PD-(L)1 Immunotherapy Response in NSCLC Patients.

Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.

SARS-CoV-2 and cancer: Are they really partners in crime?

Novel combination immunotherapy for pancreatic cancer: potent anti-tumor effects with CD40 agonist and interleukin-15 treatment.

Cold Atmospheric Plasma Treatment for Pancreatic Cancer-The Importance of Pancreatic Stellate Cells.

Oxidative Stress-Inducing Anticancer Therapies: Taking a Closer Look at Their Immunomodulating Effects.

Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies.

Critical Evaluation of the Interaction of Reactive Oxygen and Nitrogen Species with Blood to Inform the Clinical Translation of Nonthermal Plasma Therapy.

The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.

Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?

Oxidation of Innate Immune Checkpoint CD47 on Cancer Cells with Non-Thermal Plasma.

Physical plasma-derived oxidants sensitize pancreatic cancer cells to ferroptotic cell death.

Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.

Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer.

Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.

Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects.

Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.

Oxidative damage to hyaluronan-CD44 interactions as an underlying mechanism of action of oxidative stress-inducing cancer therapy.

Cold Atmospheric Plasma Increases Temozolomide Sensitivity of Three-Dimensional Glioblastoma Spheroids via Oxidative Stress-Mediated DNA Damage.

Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation.

A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy.

Auranofin and Cold Atmospheric Plasma Synergize to Trigger Distinct Cell Death Mechanisms and Immunogenic Responses in Glioblastoma.

Targeting hedgehog signaling in pancreatic ductal adenocarcinoma.

Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon hepatitis B vaccination.

Cold Atmospheric Plasma Does Not Affect Stellate Cells Phenotype in Pancreatic Cancer Tissue in Ovo.

Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by Silencing of Programmed-Death Ligands.

Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma.

Modulating the Antioxidant Response for Better Oxidative Stress-Inducing Therapies: How to Take Advantage of Two Sides of the Same Medal?

Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy.

Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects.

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.

New Implications of Patients' Sex in Today's Lung Cancer Management.

Expression of SARS-CoV-2-Related Surface Proteins in Non-Small-Cell Lung Cancer Patients and the Influence of Standard of Care Therapy.

The effect of local non-thermal plasma therapy on the cancer-immunity cycle in a melanoma mouse model.

The pro- and anti-tumoral properties of gap junctions in cancer and their role in therapeutic strategies.

The prognostic impact of the immune signature in head and neck squamous cell carcinoma.

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.

Challenges in neoantigen-directed therapeutics.

OrBITS: label-free and time-lapse monitoring of patient derived organoids for advanced drug screening.